Hbl- Hadasit Bio-holdings Ltd. · TASE:HDST-M
Hbl- Hadasit Bio-holdings — Hadasit Bio-Holdings — Investor Presentation (March 2011)
30 slides from Hbl- Hadasit Bio-holdings's investor presentation, March 2011
Slide 1: Corporate Presentation
Corporate Presentation Adv. Ophir Shahaf, CEO Hadasit Bio-Holdings Ltd. (“HBL”) (TASE: HDST) 1
Slide 2: Forward Looking Statements
Forward Looking Statements This document/presentation contains forward looking statements. Words such as “estimates,” “expects,” “intends,” “plans,” “believes” and terms of similar substance used in connection with any discussion of future operational performance or financial results, identify forwa
Slide 3: Presentation Overview
Presentation Overview Israeli Biotech HBL Profile Corporate Structure Competitive Advantages Portfolio Development Technologies Financing Milestones 3
Slide 4: Technology & Research Driving the Life Sciences Industry of Israel
Technology & Research Driving the Life sciences Industry of Israel Key Indicators
Slide 5: Israel is Currently Considered:
Israel is Currently Considered: • 1st worldwide in Medical Device Patents p. Capita, 4th in Bio- Pharma Patents • Highest civilian R&D budget out of total GDP (4.6%) • 4th in investments in Biotechnology out of total GDP • 22 drugs in advanced clinical trials (Phase II and onwards) • Rated 1-3 world
Slide 6: Israel's Investments at the Academic Stage
Israel’s Investments at the Academic Stage Israel’s GDP 2001 NIS 480B 2004 NIS 520B Over 50 % Growth 2008 NIS 740B despite recession 2009 NIS 733B R&D Expenditure (% GDP) Israel 4.46 % Japan 3.15 % USA 2.68 % Spain 1.11% • Israel focuses on investments in academic R&D
Slide 7: Life Science Patents
Life Science Patents % of TotalLifePatents Science Patents Registered % of Total Patents Registered 35 % Life Science Patents from the Total 28.3% 30 25 20 Average 15 10 17.9% 5 0 m m nd es ly el n y a da ce an en nd an pa re do Ita iu ra la at na an iw la ed Ko lg Ja ng rm Is er St Ta er Ca Fr Be S
Slide 8: Rapid and successful migration of technology from research to product
“Rapid and successful migration of technology from pure research to product developing stages, leading to revenue generating companies”.
Slide 9: Israel BioMed: Industry Roadmap
Israel BioMed : Industry Roadmap High Potential • Academic Excellence manifested by: • Entrepreneurial spirit and IP • Technology Convergence • Technology Transfer Academia to Industry • Technological incubator based companies • R&D grants to industry • Government Incentives • Infrastructure • IPO’s
Slide 10: 1998-2009: A Decade of Rapid Growth
1998-2009: A Decade of Rapid Growth 900 800 700 600 500 400 300 200 100 0 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 • Growth from 250 companies year-end 1998, to almost 800 companies in 2008 • An average of 55 new companies being formed per year over the last decade • 40% of all Life Science
Slide 11: 1998-2009: Companies' Developmental Stage
1998-2009: Companies’ Developmental Stage “Young” Industry: Pre-Clinical Approx. 50% of 12% the companies are Revenue Clinical 18% 39% in the seed/pre- clinical stages of development Other Seed 5% 26% Source: ILSI Data Base - 2009
Slide 12: The Modern Day Leap of Faith: Crossing the Valley of Death
The Modern Day Leap of Faith: Crossing the “Valley of Death” $50k - $0.5M $5M Academia, VCs, Angels, 3F’s Corporate, Institutionals, Strategic Partners
Slide 13: Hadasit Bio-Holdings: Added Value = I3
Hadasit Bio-Holdings : Added Value = I3 Innovation Investments Infrastructure • University Hospital • IPO • Jerusalem Bio-Park • 6 Teaching Faculties • Bond Financing • 6 fl., 10,000 ft.2 52% of Trans. Res. • ScientificPIPERisk • X2 is a Given. • GMP Facility • 50 Patent Families Rights Issuance • •
Slide 14: Hadasit Bio-Holdings - Profile
Hadasit Bio-Holdings - Profile Established: September 2005 Traded: Tel Aviv Stock Exchange (HDST), since January 2006 Investment rounds: (OCS – Additional $ 8 M) Stockholders: IPO (1/2006): $8m Hadasit (owned by Public CBG Bonds (8/2006): $ 5 m -- converted (Feb. 2007) Hadassah) 37% 53% 10% PIPE 1 (
Slide 15: Hadassah Medical Organization
Hadassah Medical Organization: 2 University Hospitals; Affiliated with Heb. U. Ein Kerem: 880 beds Mount Scopus: 330 beds Leveraging Hadassah Hospital Skilled personnel, infrastructure, GMP facilities, financing, Bio-Park, and clinical trials facilities R&D Excellence 52% of all translational resear
Slide 16: Corporate Structure (2.2011)
Corporate Structure (2.2011) Hadassah 100% Public CBG 37% 53% 10% 24% 87.5% 23% 30% 75% 70% 62% 92% Thrombo Bio Mar TK Signal Conju- Incure CellCure Verto ProtAb KAHR Enlivex tech Care (UK) Gate Oncology (Dx) Stem-cell Medicine Auto-immune Disease & Drug Reformulation 16
Slide 17: The Israeli Biotech Value Chain
The Israeli Biotech Value Chain Strategic Partnering Academia & Incubation Govt. Clustering & Specialized Public TTOs Support Infrastrcture Angels & VCs Company Hadasit Meytav OCS Hadassah Ofer HT HBL Rad-bio Magnet Bio-Park Glenrock Yeda BioLight Naiot BIRD Coronis Yissum Bioline Clal Bio Capital-
Slide 18: At The Forefront of the World's Biotech
At The Forefront of the World’s Biotech • Hadassah Medical Org. 52% of applied biotech research in Israel 50 new patent families a year • Scientific Advisory Board Guiding technology evaluations (e.g. Prof. Ruth Arnon – inventor of Copaxone) • Board of Directors Guiding business activities (e.g. Shl
Slide 19: Portfolio by Development Stage
Portfolio by Development Stage HBL Portfolio Company Disease Area HBL Lead Opt. Animal Preclinical Phase I Verto Lupus Enlivex GvHD Thrombotech Stroke Hadassah Hadasit KAHR Autoimmune ProtAb Autoimmune CellCure AMD BioMarCare Oncology Dx 4 Companies in phase I 3 companies to Enter Phase I/II within
Slide 20: Portfolio by Market Size
Portfolio by Market Size • Unmet clinical needs • Market size in billions Company Field/Treating Market Size Thrombotech Thrombosis, Myocardial Infarction Stroke: $ 500 mm Cardiac Arrest: $ 1 billion KAHR Medical Cancer, Inflammatory Diseases Cancer + Autoimmune diseases: $ 5 billion ProtAb Inflamma
Slide 21: Portfolio - example (I)
Portfolio – example (I) A safe, effective answer to a devastating disease • More than 30,000 bone marrow transplants worldwide per year 30% of patients develop GvHD – a devastating, fatal disease No treatment exists (Unmet Need) • Tolarex’s technology (drug and device) imitates the body’s own natura
Slide 22: Portfolio - example (II)
Portfolio – example (II) Using human Embryonic Stem Cells, to cure AMD • AMD Patient Population: US: 7 million early-stage, 1 million late-stage The leading cause of visual impairment over the age of 55; Market size: $ 10 B • Currently – no reliable supply of healthy retinal cells treated only close
Slide 23: Portfolio - example (III)
Portfolio – example (III) Successfully Treating Auto-Immune Diseases with a Unique, Proprietary New Type of Drug • Unmet clinical need in Rheumatoid Arthritis (RA) and other autoimmune diseases; Global RA market $30B • ProtAb’s first product, Proximab, is a humanized monoclonal antibody for RA with
Slide 24: Focus - Return on Investment
Focus - Return on Investment At end of Phase I HBL’s “Sweet Spot” increase in value of Highest success-to- 5x to 10x investment ratio % of total investment Approval Success Rate, per phase Percent of total investment Required investment $m Years Data: E&Y, since 1985 24
Slide 25: Biggest Growth in Value has been at Clinical Proof of Concept
Biggest Growth in Value has been at Clinical Proof of Concept Upfront only (no milestones or royalties): avg. of $ 35 M No. of Transactions $ Millions Source: Windhover’s Strategic Transactions Database, June 2007 25
Slide 26: Typical License Terms by Stage at Signing
Typical License Terms by Stage at Signing Pre- Phase I Phase II Phase III vs. 5 years clinical ago Upfront $ 3 - 10 M $ 5 - 15 M $ 10 - 25 M $40 - 100 M 3x IND $2-5M NA NA NA Ph II Start $3-8M $ 5 - 10 M NA NA Ph III Start $ 10 M $10 - 15 M $ 25 M NA 3x NDA Filing $5M $5M $ 10 M $ 30 M 1st Approval
Slide 27: External Investments in Companies
External Investments in Companies Major Strategic Investors / Partners invested in HBL Portfolio Companies: TEVA Pharmaceutical Industries: $ 1 M in Cell Cure Neurosciences – Recognition of leadership in hESC field Creation of Value: – Attractive terms for company (value, rights) • Additional Funds
Slide 28: 2011-2012: Milestones
2011-2012: Milestones Enlivex – Phase I/IIa under way – Phase I results, Listing on US exchange (OTC), external inv. ($ 4-5 M) Thrombotech – Phase I completed successfully. Phase IIa to start ProtAb – Big-pharma collaboration, IP, Manuf. of Humanized mAb for Clin Trial, FDA approval for Phase I/IIa
Slide 29: Summary
Summary • $ 10 M in liquid assets (1/9/10), completed closing of PIPE and Rights Issuance - over NIS 40 M during 2009 • 3 companies raising $ 3-10 M each. 4 of 7 companies in the clinic. • All companies show major progress since HBL Investment • Timeline: 3 additional companies in Phase I within 18
Slide 30: Thank You
Thank You Contact: Ophir Shahaf, CEO E: ophir@hbl.co.il T: +972-2-677-8757 M: +972-54-520-1177 30
Hadasit Bio-Holdings — Investor Presentation (March 2011) on 6ix